Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 11/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 11/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.50 |
| ▸ | CDC42 | P60953 | 1/20 | 0.50 |
| ▸ | RAC1 | P63000 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27382505 | 0.89 | L3MBTL1 (0.49) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL6487655 | 0.89 | AKR1C3 (0.51) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL24893698 | 0.80 | L3MBTL1 (0.42) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL30207133 | 0.80 | L3MBTL1 (0.42) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL24893703 | 0.80 | L3MBTL1 (0.42) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL2737341 | 0.79 | L3MBTL1 (0.55) | PTGS1L3MBTL1CYP2A6 | |
| SCHEMBL15730569 | 0.78 | L3MBTL1 (0.54) | L3MBTL1CYP2A6 | |
| SCHEMBL20559505 | 0.76 | L3MBTL1 (0.53) | L3MBTL1CYP2A6 | |
| SCHEMBL20559506 | 0.76 | L3MBTL1 (0.53) | L3MBTL1CYP2A6 | |
| SCHEMBL8391241 | 0.76 | BACE1 (0.49) | AKR1C3AKR1C2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101475526-B | Carboxylic acid derivatives inhibiting the binding of integrins to receptors thereof | TEXAS BIOTECHNOLOGY CORP | 2011-05-25 | — | — | CN | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| CN-101475526-A | Carboxylic acid derivatives inhibiting the binding of integrins to receptors thereof | TEXAS BIOTECHNOLOGY CORP (US) | 2009-07-08 | — | — | CN | disclosed |
| CN-100491353-C | Carboxylic acid derivatives inhibiting the binding of integrins to their receptors | TEXAS BIOTECHNOLOGIES CORP (US) | 2009-05-27 | — | — | CN | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | AKR1C3 809/4885AKR1C2 844/4885PTGS2 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.